Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Study of Metformin and S. Baicalensis Combination Therapy in Type 2 Diabetes Mellitus Patients

Condition:   Diabetes Mellitus
Interventions:   Drug: Combination of Metformin + S. Baicalensis;   Drug: Combination of Metformin + Placebo
Sponsor:   Namyi Gu
Recruiting - verified July 2016

Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

Condition:   Diabetes Mellitus Type 2
Intervention:  
Sponsors:   AstraZeneca;   Truven health
Not yet recruiting - verified July 2016

Metformin Use in Chronic Kidney Disease: The CKD-Met Study

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Intervention:   Other: modalities of metformin prescription
Sponsor:   Hospices Civils de Lyon
Recruiting - verified July 2016

Circulating microRNAs for Discriminating Obese Preschoolers at Risk of Diabetes

Condition:   Discriminate Obese Children at Risk for Diabetes.
Intervention:  
Sponsor:   Nanjing Medical University
Completed - verified July 2016

A Randomized, Placebo-controlled, Double Blind Trial to Investigate Whether Vitamin K2 Can Influence Arterial Calcification in Patients With Type 2 Diabetes

Conditions:   Arterial Calcification;   Diabetes Mellitus Type 2
Interventions:   Dietary Supplement: Menaquinone-7;   Dietary Supplement: Placebo
Sponsor:   UMC Utrecht
Recruiting - verified July 2016

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: GLP1 receptor agonist;   Drug: basal insulin;   Drug: SGLT2 inhibitor;   Drug: Metformin
Sponsor:   University of California, San Francisco
Not yet recruiting - verified July 2016

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Not yet recruiting - verified July 2016

Integrative Care for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Other: Naturopathic Care;   Other: Usual (Conventional) Care
Sponsor:   The Canadian College of Naturopathic Medicine
Not yet recruiting - verified July 2016

Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Irbesartan/atorvastatin fixed dose combination;   Drug: Irbesartan SR47436;   Drug: Atorvastatin
Sponsor:   Sanofi
Not yet recruiting - verified July 2016

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sub cutaneous liraglutide;   Drug: Oral Vildagliptin
Sponsors:   Yaounde Central Hospital;   University of Yaounde 1;   University of Buea
Recruiting - verified July 2016

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

Condition:   Diabetes
Intervention:   Biological: Human Pancreatic Islet Transplantation
Sponsors:   Rodolfo Alejandro;   Diabetes Research Institute Foundation;   Bascom Palmer Eye Institute
Not yet recruiting - verified July 2016

Glucose Homeostasis and Incretin Effect T2DM in the Youth- a Study of the Malaysian Population

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: OGTT and IVGTT tests
Sponsors:   Penang Medical College;   Sarawak General Hospital;   Putrajaya Hospital, Malaysia;   Penang Hospital, Malaysia;   Institute of Neuroscience, Padova, Italy;   University of Copenhagen;   Institute for Medical Research, Malaysia;   Seberang Jaya Clinical Research Centre
Completed - verified July 2016

Effect of a Continuous Glucose Monitoring on Maternal and Neonatal Outcomes in Gestational Diabetes Mellitus

Condition:   GDM
Interventions:   Device: FreeStyle sensors.;   Device: Glucometer
Sponsor:   Tel-Aviv Sourasky Medical Center
Not yet recruiting - verified July 2016

Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE;   Drug: metformin;   Drug: repaglinide;   Drug: acarbose;   Drug: sitagliptin
Sponsor:   Sanofi
Not yet recruiting - verified July 2016

The Canadian E-PAraDiGM (Exercise Physical Activity and Diabetes Glucose Monitoring) Protocol

Conditions:   Walking;   Seated Control
Interventions:   Behavioral: Walking;   Behavioral: Seated Control
Sponsors:   University of British Columbia;   University of Alberta;   University of Calgary;   McMaster University;   Université de Sherbrooke;   Centre Hospitalier de l'Université Laval;   Children's Hospital Research Institute of Manitoba;   Medtronic
Recruiting - verified July 2016

Diabetes Complication Control in Community Clinics (D4C) Trial

Conditions:   Diabetes;   Hypertension;   Dyslipidemia;   Cardiovascular Disease
Intervention:   Other: Protocol-based integrated care
Sponsors:   Tulane University Health Sciences Center;   Xiamen Diabetes Institute, Xiamen University, Xiamen, China
Not yet recruiting - verified July 2016

Wolfram Syndrome International Registry and Clinical Study

Conditions:   Wolfram Syndrome;   Diabetes Mellitus;   Optic Nerve Atrophy;   Deafness;   Diabetes Insipidus;   Ataxia
Intervention:  
Sponsors:   Washington University School of Medicine;   American Diabetes Association;   National Institutes of Health (NIH)
Recruiting - verified July 2016

Enhancing Self-Management Support in Diabetes Through Patient Engagement

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Enhanced Engagement Protocol for CTH (EE-CTH);   Behavioral: Connection to Health (CTH)
Sponsors:   University of California, San Francisco;   University of Colorado, Denver
Not yet recruiting - verified July 2016

Assessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)

Conditions:   Pre-diabetes;   Diabetes
Intervention:   Procedure: Not applicable. This is an observational study.
Sponsors:   Medicine;   Janssen Pharmaceuticals;   National Medical Research Council (NMRC), Singapore
Recruiting - verified July 2016

A Study of Autologous Neo-Kidney Augment™ (NKA) in Type 2 Diabetics With Chronic Kidney Disease

Condition:   Diabetic Chronic Kidney Disease
Intervention:   Biological: Neo-Kidney Augment (NKA)
Sponsors:   RegenMed (Cayman) Ltd.;   CTI Clinical Trial and Consulting Services
Not yet recruiting - verified July 2016

Effect of FISH Intake on MEtabolic Health in a Diabetic South Asian popuLation (FISH MEAL)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Tinned mackerel fish
Sponsor:   University of Aberdeen
Not yet recruiting - verified July 2016

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Metformin IR
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified July 2016

Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Dietary Supplement: Folic acid;   Dietary Supplement: Vitamin B12;   Drug: Oral hypoglycemic agents [Metformin +/- Sulfonylurea]
Sponsor:   All India Institute of Medical Sciences, Bhubaneswar
Not yet recruiting - verified July 2016

Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Oral administration of Ipragliflozin
Sponsors:   Asan Medical Center;   Severance Hospital;   Samsung Medical Center;   Kyung Hee University Hospital at Gangdong;   Astellas Pharma Korea, Inc.
Recruiting - verified July 2016

Shared Medical Visits for Spanish-speaking Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Intervention:   Behavioral: Shared Medical Visit
Sponsor:   University of Nebraska
Recruiting - verified July 2016

The Effect of Non-surgical Periodontal Therapy Plus Doxycycline on HbA1c in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus With Periodontal Disease
Interventions:   Drug: Doxycycline Group;   Drug: placebo Group
Sponsor:   Islamic Azad University, Tehran
Active, not recruiting - verified July 2016

An Exploratory Study to Evaluate the Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability for One Week With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Trelagliptin;   Drug: Alogliptin
Sponsor:   Takeda
Recruiting - verified July 2016

PRE-STARt Intervention - Trial of an Interactive Family Based Lifestyle Programme

Conditions:   Type 2 Diabetes;   Chronic Disease;   Obesity
Intervention:   Behavioral: Interactive Lifestyle programme workshop
Sponsors:   University Hospitals, Leicester;   University of Leicester;   Associacao Protectora dos Diabeticos de Portugal;   Algarve Regional Health Administration, Portugal;   University of Leipzig;   Technische Universität Dresden;   Education Institute Thessaloniki, Greece;   Diabetes Centre of Paediatrics P&A;   Primary Care Centre Egia, San Sebastian, Spain;   Basque Government Department of Public Health;   Health Department of the Alto/Bajo Deba, Spain
Not yet recruiting - verified July 2016

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified July 2016

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions:   Biological: Evolocumab;   Other: Placebo to Evolocumab
Sponsor:   Amgen
Recruiting - verified July 2016

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo to stiagliptin;   Drug: Metformin;   Drug: Metformin XR;   Drug: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Validation of an Integrated Attention Model for Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Behavioral: CAIPaDi
Sponsor:   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Recruiting - verified July 2016

Effect of Non Surgical Treatment of Periodontitis on Diabetes Control

Conditions:   Periodontitis;   Diabetes
Intervention:   Procedure: non-surgical periodontal treatment
Sponsor:   Yaounde Central Hospital
Completed - verified July 2016

An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Janssen-Cilag International NV
Active, not recruiting - verified July 2016

A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY900014;   Drug: Insulin Lispro
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified July 2016

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified May 2016

Intraluminal Imaging of Duodenal Layer Morphometry in Patients With and Without Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Procedure: EUS and OCT imaging
Sponsor:   Victoria Gomez
Enrolling by invitation - verified July 2016

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin;   Drug: Repaglinide;   Drug: Pioglitazone;   Drug: Gliclazide;   Drug: Glimepiride
Sponsors:   University of Leicester;   University Hospital Birmingham
Recruiting - verified July 2016

The Effectiveness of Diabetes Self-Management Education Program Based on Behavioural Change Theory

Conditions:   Health Behavior;   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Diabetes Self-Management Education
Sponsor:   University of Nottingham
Active, not recruiting - verified July 2016

DPP4 Inhibition & Beta Cell Function

Condition:   Healthy
Interventions:   Drug: Active Comparator: Sitagliptin;   Drug: Placebo Comparator - No Sitagliptin
Sponsors:   David D'Alessio, M.D.;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified July 2016

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified July 2016

Metabolic Effects of Angiotensin-(1-7)

Conditions:   Obesity;   Insulin Resistance;   Hypertension;   Metabolic Cardiovascular Syndrome
Interventions:   Drug: Angiotensin-(1-7);   Drug: Saline
Sponsor:   Vanderbilt University
Recruiting - verified July 2016

Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: INSULIN GLARGINE
Sponsor:   Sanofi
Recruiting - verified July 2016

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Placebo;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

Conditions:   Diabetes Mellitus, Type 2;   Coronary Artery Disease;   Cardiovascular Diseases
Interventions:   Drug: RVX000222;   Drug: Placebo (for RVX000222);   Drug: atorvastatin;   Drug: rosuvastatin
Sponsors:   Resverlogix Corp;   PPD;   ICON plc;   Medidata Solutions
Recruiting - verified July 2016

Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2016

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

Conditions:   Dyslipidemia;   Type II Diabetes
Interventions:   Drug: YH14755;   Drug: Metformin;   Drug: Rosuvastatin
Sponsor:   Yuhan Corporation
Recruiting - verified July 2016

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: Forxiga;   Behavioral: Lifestyle therapy
Sponsors:   Population Health Research Institute;   AstraZeneca
Recruiting - verified July 2016

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PF-06291874;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified July 2016

A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MEDI0382;   Drug: Placebo
Sponsor:   MedImmune LLC
Recruiting - verified July 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified July 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified July 2016

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents

Condition:   Diabetes Mellitus, Type 2 (T2DM)
Interventions:   Device: Bolus Insulin Patch (Calibra Finesse);   Device: Insulin Pen (Novo-Nordisk FlexPen®)
Sponsors:   Calibra Medical, Inc.;   Medpace, Inc.
Recruiting - verified July 2016

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Matching placebo to sitagliptin;   Drug: Matching placebo to dapagliflozin;   Drug: Sulfonylurea
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

Conditions:   Chronic Kidney Disease;   Type 2 Diabetes
Intervention:   Biological: Neo-Kidney Augment
Sponsors:   RegenMed (Cayman) Ltd.;   CTI Clinical Trial and Consulting Services
Enrolling by invitation - verified July 2016

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Conditions:   Essential Hypertension;   Type 2 Diabetes Mellitus
Intervention:   Drug: Azilsartan Medoxomil
Sponsor:   Takeda
Recruiting - verified July 2016

Online Support for Diabetes Self-Management

Condition:   Diabetes Mellitus Type 2
Intervention:   Behavioral: Online Support
Sponsors:   University of British Columbia;   University of Minnesota - Clinical and Translational Science Institute
Terminated - verified July 2016

Complications in Central American Diabetic Patients: Historic Cohort

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: None, observational study
Sponsors:   Clínica Los Yoses;   Novo Nordisk A/S
Completed - verified July 2016

Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes - Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients - The Phenotype Study

Condition:   Type 2 Diabetes
Interventions:   Other: Low carbohydrate meals;   Other: Standard carbohydrate meals
Sponsor:   Bispebjerg Hospital
Recruiting - verified July 2016

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus

Condition:   Diabetes Mellitus Gestational Previous Pregnancy
Intervention:   Behavioral: Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus
Sponsor:   Athabasca University
Recruiting - verified July 2016

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: ASP1941;   Drug: Placebo
Sponsor:   Astellas Pharma Korea, Inc.
Active, not recruiting - verified July 2016

Nicotinic Agonist Effects on BMI and Neuronal Response

Condition:   Obesity
Interventions:   Drug: DMXB-A;   Other: Placebo
Sponsor:   University of Colorado, Denver
Recruiting - verified July 2016

Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study

Condition:   Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions:   Drug: Metformin;   Behavioral: Lifestyle modifications;   Device: Fibroscan device (Echosens)
Sponsor:   Northwell Health
Recruiting - verified July 2016

Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death

Conditions:   Tissue and Organ Harvesting;   Liver Transplantation;   Brain Death
Intervention:   Procedure: Fibroscan
Sponsor:   University Hospital, Limoges
Recruiting - verified July 2016

A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Device: PaQ® Insulin Delivery Device;   Drug: Insulin, Asp(B28)-
Sponsor:   CeQur Corporation
Completed - verified July 2016

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GLWL-01, Part A;   Drug: Placebo, Part A;   Drug: GLWL-01, Part B;   Drug: Placebo, Part B;   Drug: GLWL-01, Part C;   Drug: Placebo, Part C
Sponsor:   GLWL Research Inc.
Recruiting - verified July 2016

Effectiveness of Automated Mobile Phone Based Text Messaging on the Improvement of Glycaemic Outcomes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Mobile phone text messaging;   Other: Conventional care
Sponsor:   India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
Active, not recruiting - verified July 2016

Effect of a Low Glycemic Index on Metabolic Syndrome

Condition:   Metabolic Syndrome X
Interventions:   Behavioral: Mediterranean Diet;   Behavioral: Low Glycemic Index Diet;   Behavioral: Low Glycemic Index Mediterranean Diet
Sponsor:   Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Completed - verified July 2016

Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Interventions:   Procedure: Bariatric surgery involving Roux-en-Y gastric bypass;   Procedure: Bariatric surgery involving Laparoscopic adjustable gastric banding;   Procedure: Bariatric surgery involving Laparoscopic sleeve gastrectomy
Sponsors:   The Cleveland Clinic;   Medtronic - MITG;   Ethicon, Inc.
Enrolling by invitation - verified July 2016

Effect of Cycloset on Glycemic Control When Added to GLP-1 Analogue Therapy

Condition:   Type 2 Diabetes
Intervention:   Drug: Cycloset
Sponsors:   The University of Texas Health Science Center at San Antonio;   VeroScience
Recruiting - verified July 2016

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   AstraZeneca;   Ono Pharmaceutical Co. Ltd
Active, not recruiting - verified July 2016

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified July 2016

Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Completed - verified July 2016

Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified July 2016

Continuous Glucose Monitoring in Controls With and Without Cystic Fibrosis

Condition:   Cystic Fibrosis
Intervention:  
Sponsor:   University of Colorado, Denver
Recruiting - verified July 2016

A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: PaQ® Insulin Delivery Device
Sponsor:   CeQur Corporation
Terminated - verified July 2016

Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Mitiglinide;   Drug: Acarbose
Sponsor:   Zhongda Hospital
Completed - verified July 2016

Translating Telephonic Diabetes Self-management Support to Primary Care Practice

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Telephonic Diabetes Self-Management Support;   Other: Educational Print Materials
Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   New York City Department of Health and Mental Hygiene
Recruiting - verified July 2016

Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Matching Placebo to Ertugliflozin 5 mg;   Drug: Matching Placebo to Ertugliflozin 10 mg;   Drug: Matching Placebo to sitagliptin 100 mg;   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Sitagliptin 100 mg;   Drug: Metformin >= 1500 mg/day;   Biological: Insulin Glargine Rescue Medication;   Drug: Glimepiride Rescue Medication
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified July 2016

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Condition:   Essential Hypertension Complicated by Type 2 Diabetes Mellitus
Interventions:   Drug: Azilsartan;   Drug: Telmisartan
Sponsor:   Takeda
Completed - verified July 2016

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified July 2016

Efficacy and Safety of Voglibose Compared With Acarbose in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin;   Drug: Voglibose;   Drug: Acarbose
Sponsor:   Takeda
Completed - verified July 2016

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Conditions:   Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
Interventions:   Drug: APD356-Lorcaserin hydrochloride;   Drug: Placebo
Sponsors:   Eisai Inc.;   Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
Active, not recruiting - verified July 2016

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Drug: Liraglutide;   Drug: Metformin
Sponsor:   University of Miami
Recruiting - verified July 2016

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Cardiovascular Disease
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Placebo;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Specific Clinical Experience Investigation for Long-term Use of Bydureon

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

The Effect of Linagliptin on Mitochondrial and Endothelial Function

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: Linagliptin;   Drug: Placebo;   Other: Microcirculation testing;   Other: Macrocirculation testing;   Other: MRI Scans
Sponsor:   Beth Israel Deaconess Medical Center
Completed - verified July 2016

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Studies Investigating Co-morbidities Aggravating Heart Failure

Conditions:   Heart Failure;   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   Charite University, Berlin, Germany;   University of Hull;   Wroclaw Medical University;   IRCCS San Raffaele;   Hannover Medical School;   Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health;   Moscow State University of Medicine and Dentistry;   Siberian Branch of the Russian Academy of Medical Sciences;   Russian Cardiology Research and Production Center;   The University Clinic of Pulmonary and Allergic Diseases Golnik;   Silesian Centre for Heart Diseases
Completed - verified July 2016

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified July 2016

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified July 2016

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified July 2016

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer

Condition:   Prostatic Neoplasms
Interventions:   Drug: METFORMIN;   Drug: Placebo;   Drug: TAXOTERE®
Sponsor:   Centre Antoine Lacassagne
Active, not recruiting - verified June 2016

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Eye Blood Flow and the Kidney

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Captopril;   Drug: placebo
Sponsor:   Brigham and Women's Hospital
Recruiting - verified July 2016

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified July 2016

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: PaQ™ insulin infusion device
Sponsors:   CeQur Corporation;   International Diabetes Center at Park Nicollet
Completed - verified July 2016

Impact of Exenatide on Sleep Duration

Condition:   Type 2 Diabetes
Intervention:   Drug: Exenatide
Sponsor:   University of Chicago
Recruiting - verified July 2016

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

Conditions:   Insulin Sensitivity;   Multiple Mitochondrial Dysfunctions Syndrome
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   The University of Texas Health Science Center at San Antonio;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2016

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Exenatide;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Amylin Pharmaceuticals, LLC.;   Eli Lilly and Company
Completed - verified July 2016

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions:   Diabetes;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Enrolling by invitation - verified July 2016

DEMOJUAN- DEMOnstration Area for Primary Prevention of Type 2 Diabetes, JUAN Mina and Barranquilla, Colombia

Conditions:   Type 2 Diabetes;   Glucose Metabolism Disorders
Interventions:   Behavioral: Lifestyle intervention (nutrition);   Behavioral: Lifestyle intervention (physical activity)
Sponsors:   Centro de Investigacion Sanitaria;   International Diabetes Federation;   Helsinki University
Completed - verified July 2016

Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients

Condition:   Osseointegration Failure of Dental Implant From Complication of Systemic Disease
Intervention:  
Sponsors:   University of Alabama at Birmingham;   Dentsply Implants
Active, not recruiting - verified June 2016

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

Condition:   Diabetes
Interventions:   Drug: metformin\pioglitazone\exenatide;   Drug: metformin, glyburide and glargine
Sponsors:   The University of Texas Health Science Center at San Antonio;   American Diabetes Association;   Amylin Pharmaceuticals, LLC.
Recruiting - verified July 2016

Effects of Continuous Positive Airway Pressure (CPAP)Treatment on Glucose Control

Conditions:   Obstructive Sleep Apnea;   Type 2 Diabetes
Intervention:   Device: Continuous Positive Airway Pressure (CPAP) Therapy (active or placebo)
Sponsor:   University of Chicago
Active, not recruiting - verified July 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2016

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: exenatide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2016

A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes

Conditions:   Diabetes;   Type 1 Diabetes Mellitus;   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   Baylor College of Medicine
Completed - verified July 2016

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified July 2016

Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: ruboxistaurin;   Other: placebo
Sponsor:   Chromaderm, Inc.
Completed - verified July 2016

Effect of LY333531 on Vascular and Neural Functions

Condition:   Diabetes Mellitus
Interventions:   Drug: Ruboxistaurin;   Drug: Placebo
Sponsors:   Chromaderm, Inc.;   Joslin Diabetes Center
Completed - verified July 2016

Empowering Patients to Better Manage Diabetes Through Self-Care

Condition:   Type I or Type II Diabetes (Excludes Gestational Diabetes)
Interventions:   Behavioral: Pharmacist Counseling;   Behavioral: Educational materials
Sponsors:   Oregon State University;   Sanofi
Completed - verified July 2016

Non-Traditional Cardiovascular Risk Factors in Type 2 Diabetes Mellitus - Ancillary to VA Study of Glycemic Control

Conditions:   Atherosclerosis;   Cardiovascular Diseases;   Diabetes Mellitus;   Diabetes Mellitus, Non-insulin Dependent;   Heart Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2008